Penumbra (FRA:0P8) Cyclically Adjusted Revenue per Share: €19.95 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0P8 Penumbra Inc FRA:0P8
90 GF Score
Price €277.20
GF Value €292.33
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Penumbra Cyclically Adjusted Revenue per Share?

Penumbra FRA:0P8 -0.29% 90 Cyclically Adjusted Revenue per Share is €19.95 as of Mar. 2026. GuruFocus rates FRA:0P8 with a GF Score™ of 90/100 and a GF Value™ of €292.33 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Penumbra's adjusted revenue per share for the three months ended in Mar. 2026 was €8.198. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €19.95 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Penumbra's average Cyclically Adjusted Revenue Growth Rate was 15.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-23), Penumbra's current stock price is €277.20. Penumbra's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €19.95. Penumbra's Cyclically Adjusted PS Ratio of today is 13.89.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Penumbra was 16.30. The lowest was 9.44. And the median was 13.02.


Penumbra  (FRA:0P8) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Penumbra's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=277.20/19.95
=13.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Penumbra was 16.30. The lowest was 9.44. And the median was 13.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Penumbra Cyclically Adjusted Revenue per Share Related Terms


Penumbra Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Penumbra's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Penumbra Cyclically Adjusted Revenue per Share Chart

Penumbra Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 18.44 18.88

Penumbra Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.55 17.72 18.11 18.88 19.95

FRA:0P8 vs GMED, PODD, BRKR: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Penumbra's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Penumbra Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Penumbra's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Penumbra's Cyclically Adjusted PS Ratio falls into.


FRA:0P8
90GF Score
Penumbra Inc FRA:0P8
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Penumbra Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Penumbra's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=8.198/330.2130*330.2130
=8.198

Current CPI (Mar. 2026) = 330.2130.

Penumbra Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.740 241.018 2.384
201609 1.773 241.428 2.425
201612 2.050 241.432 2.804
201703 2.165 243.801 2.932
201706 2.159 244.955 2.910
201709 1.974 246.819 2.641
201712 1.888 246.524 2.529
201803 2.319 249.554 3.069
201806 2.599 251.989 3.406
201809 2.798 252.439 3.660
201812 2.517 251.233 3.308
201903 3.139 254.202 4.078
201906 3.280 256.143 4.228
201909 3.492 256.759 4.491
201912 3.598 256.974 4.623
202003 3.418 258.115 4.373
202006 2.637 257.797 3.378
202009 3.542 260.280 4.494
202012 3.773 260.474 4.783
202103 3.787 264.877 4.721
202106 4.069 271.696 4.945
202109 4.297 274.310 5.173
202112 4.660 278.802 5.519
202203 4.783 287.504 5.494
202206 5.219 296.311 5.816
202209 5.692 296.808 6.333
202212 5.491 296.797 6.109
202303 5.770 301.836 6.312
202306 6.157 305.109 6.664
202309 6.473 307.789 6.945
202312 6.640 306.746 7.148
202403 6.509 312.332 6.882
202406 7.170 314.175 7.536
202409 6.923 315.301 7.250
202412 7.358 315.605 7.699
202503 7.656 319.799 7.905
202506 7.499 322.561 7.677
202509 7.689 324.800 7.817
202512 8.350 324.054 8.509
202603 8.198 330.213 8.198

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €19.95 mean?
Penumbra (FRA:0P8) has a Cyclically Adjusted Revenue per Share of €19.95 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Penumbra and its competitors.
Is Penumbra's Cyclically Adjusted Revenue per Share too high?
Penumbra's current Cyclically Adjusted Revenue per Share is €19.95. Overall, Penumbra has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Penumbra's Cyclically Adjusted Revenue per Share compare to GMED and PODD?
Penumbra's Cyclically Adjusted Revenue per Share of €19.95 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Penumbra and its competitors. Penumbra's current Cyclically Adjusted Revenue per Share is €19.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Penumbra stock overvalued right now?
Based on GuruFocus' analysis, Penumbra (FRA:0P8) is currently considered Fairly Valued. The stock's GF Value™ is €292.33, compared to a current price of €277.20 — trading 5.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €19.95. Penumbra's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Penumbra (FRA:0P8), the current Cyclically Adjusted Revenue per Share is €19.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Penumbra (FRA:0P8) Overvalued in 2026?

Based on GuruFocus' analysis, Penumbra stock appears to be undervalued. The current stock price of €277.20 is trading 5.2% below its estimated GF Value™ of €292.33. GuruFocus considers Penumbra to be Fairly Valued.

Key valuation signals for FRA:0P8:

  • Cyclically Adjusted Revenue per Share: €19.95
  • GF Value™: €292.33 vs. price of €277.20 (5.2% below fair value)
  • GF Score™: 90/100 with 1 warning sign

No single metric tells the full story. See the FRA:0P8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Penumbra Business Description

Other Exchanges PEN:USA
Address 1310 Harbor Bay Parkway, One Penumbra Place, Alameda, CA, USA, 94502
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
90GF Score

Get the complete analysis for FRA:0P8

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€277.20
Price
€292.33
GF Value